Literature DB >> 7172411

Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.

R Baurain, D Deprez-De Campeneere, A Zenebergh, A Trouet.   

Abstract

When injected rapidly IV into rabbits, the plasma levels of free DOX decreased biphasically and the drug was distributed in a volume greater than the body volume. When given as a DNA complex, the area under the concentration versus time curve was increased 10-fold and the distribution volume reduced more than 100-fold. The DOX-DNA complex infused both in rabbits and in human patients reached steady state-concentrations 10 and 20 times higher, respectively, than free DOX infusion, and the distribution volumes were reduced accordingly. These results confirm that the observed lower cardiotoxicity of the DOX-DNA complex arises despite higher plasma concentrations of the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7172411     DOI: 10.1007/bf00265386

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Clinical and pharmacologic studies with adriamycin-DNA complex in children with malignant disease.

Authors:  S O Lie; K K Lie; A Glomstein
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 2.  Perspectives in cancer research. Increased selectivity of drugs by linking to carriers.

Authors:  A Trouet
Journal:  Eur J Cancer       Date:  1978-02       Impact factor: 9.162

3.  Adriamycin and daunorubicin disposition in the rabbit.

Authors:  N R Bachur; R C Hildebrand; R S Jaenke
Journal:  J Pharmacol Exp Ther       Date:  1974-11       Impact factor: 4.030

4.  In vitro iodination of DNA. Maximizing iodination while minimizing degradation; use of buoyant density shifts for DNA-DNA hybrid isolation.

Authors:  J M Orosz; J G Wetmur
Journal:  Biochemistry       Date:  1974-12-31       Impact factor: 3.162

5.  Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex.

Authors:  A Trouet; D Deprez-de Campeneere; M de Smedt-Malengreaux; G Atassi
Journal:  Eur J Cancer       Date:  1974-07       Impact factor: 9.162

6.  Iodination of nucleic acids in vitro.

Authors:  S L Commerford
Journal:  Biochemistry       Date:  1971-05-25       Impact factor: 3.162

7.  Comparative studies of the accumulation of doxorubicin and doxorubicin-DNA in various cell lines.

Authors:  A Zenebergh; Y J Schneider; A Trouet
Journal:  Biochem Pharmacol       Date:  1980-04-01       Impact factor: 5.858

8.  DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Authors:  Y J Schneider; R Baurain; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Authors:  A Trouet; M Masquelier; R Baurain; D Deprez-De Campeneere
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

10.  Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

Authors:  D Deprez-De Campeneere; R Baurain; M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

View more
  5 in total

1.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

Authors:  J Ninane; R Baurain; A de Selys; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Cytofluorescence localization of adriamycin in resistant colon cancer cells.

Authors:  B Chauffert; F Martin; A Caignard; J F Jeannin; A Leclerc
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Authors:  P Gunvén; N O Theve; C Peterson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.